Observational study on triple negative adult B-cell acute lymphoblastic leukemia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter, non-interventional study focuses on adult patients diagnosed with triple negative B-cell acute lymphoblastic leukemia (B-ALL). It aims to improve the understanding of this leukemia subtype by analyzing genetic alterations that may predict treatment outcomes. Physicians will make treatment decisions based on their clinical judgment, independent of the study participation. The study seeks to gather clinical data to enhance the molecular characterization of triple negative B-ALL and identify potential targeted therapies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Participant is willing and able to give informed consent for participation in the study;
* Patients with new diagnosis and/or relapse/s of primary or secondary B-ALL;
* Negative for BCR-ABL1 t(9;22); TCF3-PBX1 t(1;19); MLL-AF4 t(4;11) rearrangements;
* Participant is willing and able to give informed consent for participation in the study;
* Male or Female, aged \>18 years;
* Availability of clinical data.

Exclusion Criteria:

* Age \< 18 years;
* B-ALL positive for BCR-ABL1 t(9;22); TCF3-PBX1 t(1;19); MLL-AF4 t(4;11) rearrangements.

Low blast percentage (\<70%) samples could be excluded for molecular evaluations, not for cytofluorimetric analyses;

Where it's running

• Irst Irccs
  Meldola, Fc, Italy Recruiting
• Ospedale S. Maria delle Croci RAVENNA
  Ravenna, Ra, Italy Recruiting
• Ospedale Infermi
  Rimini, Rn, Italy Recruiting

Study contacts

• Study coordinator: Oriana Nanni, Dr
• Email: oriana.nanni@irst.emr.it
• Phone: +39 0543739100

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Breath analysis to detect fungal infections in leukemia patients

  This study is testing if analyzing breath samples can help doctors detect fungal infections in leukemia patients who are at high risk due to their treatment.

  Recruiting University of Zurich · Zurich, Canton of Zurich · NCT06537726

• Low-dose Liposomal Amphotericin B for preventing fungal infections in adults with blood cancers and prolonged neutropenia

  This study tests whether giving a daily 50 mg dose of liposomal amphotericin B can help prevent invasive fungal infections in adults with blood cancers who have prolonged low white blood cell counts.

  Recruiting Haikou Affiliated Hospital of Central South University Xiangya School of Medicine · Hainan, Hainan · NCT07763054

• Observatory of adults with Ph+ ALL receiving BCR-ABL1 inhibitors with chemotherapy, steroids, or monoclonal antibodies

  This study follows adults with Philadelphia-positive acute lymphoblastic leukemia who are being treated with a combination of BCR-ABL1 inhibitors and other therapies to see how they fare in real-world practice.

  Recruiting at 7 sites Versailles Hospital · Amiens and 22 other locations · NCT07684131

• Strength Training for Kids with Acute Lymphoblastic Leukemia and Lymphoblastic L lymphoma

  Researchers are testing a structured strength-training program for children and teens recently diagnosed with ALL or lymphoblastic lymphoma to see if it helps with weight gain and physical function during treatment.

  Recruiting UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT07634653

• FXS0683 in relapsed or refractory blood cancers

  This first‑in‑human study tests FXS0683 in adults with relapsed or refractory B‑cell lymphoma, AML, MDS, or ALL to see if it is safe, how the drug behaves in the body, and whether it shows any antitumor activity.

  Recruiting Phase 1 Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · Tianjin, Tianjin Municipality · NCT07616089

• CD19-targeted CAR-T cells that make p40 for relapsed or refractory CD19-positive blood cancers

  This trial will try a patient's own CD19-directed CAR-T cells engineered to produce p40 to see if they work better and last longer in adults with relapsed or refractory CD19-positive blood cancers.

  Recruiting Phase 1/2 Shenzhen University General Hospital · Shenzhen, Other (Non U.s.) · NCT07584889

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.